4. 4) og thromboxan A2- binding ved niveauer, der var konsistente med den eksponering der er set hos patienter i behandling med Aptivus/ ritonavir blev det observeret, at tipranavir hæmmer blodplade- aggregationen.
In in-vitro studies, tipranavir was found to inhibit platelet aggregation when using human platelets (see section 4.4) and thromboxane A2 binding in an in vitro cell model at levels consistent with exposure observed in patients receiving APTIVUS/ ritonavir.